It can be seen from these studies that Wee1, CHK1, PARP, and others are all valuable targets in the treatment of gastric cancer, and the combination of different target-related inhibitors may be a more effective strategy for the treatment of gastric cancer in the future, which improves the overall treatment outcome in patients with advanced gastric cancer. Here, PARP1 is linked to gastric cancer.